Clinical trials: Fungal Disease
Vulvovaginal Candidiasis, Vaginal Yeast Infections
Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
Vaginitis is one of the most common gynecological problems in women. Candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common.
- Trial name
- NCT05895162
- Testing
- JUVIA zinc containing vaginal gel treatment, Fluconazole 150Mg Tab
- Where
- Hungary
- Volunteers
- 64 people
- Sponsor
- FEMPHARMA Kft.
Bacteremia
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
In vitro identification of S. aureus,methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)from positive blood culture using MicroPhage's bacteriophage-based diagnostic platform.
- Trial name
- NCT01640886
- Where
- 3 sites in United States
- Volunteers
- 764 people
- Sponsor
- MicroPhage, Inc.
Fungal Infection
Vfend Special Investigation For Prophylaxis
Examine the safety and effectiveness of Vfend [voriconazole] for prophylaxix use under general clinical practices.
- Trial name
- NCT02674685
- Volunteers
- 241 people
- Sponsor
- Pfizer
Diphtheria, Tetanus
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine
The purpose of this study is to evaluate the long term immunogenicity produced in children by the investigational hexavalent vaccine (DTaP-IPV-Hep B-PRP-T) given in Study A3L15 (NCT 00362336).
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01105559
- Where
- 2 sites in South Africa
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sanofi
Tuberculosis
Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection
This is a doble-blind, masked, compared with placebo clinical trial in pediatric population in contact with tuberculosis with or without tuberculosis infection.
- Trial name
- NCT02581579
- Testing
- Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
- Where
- 3 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Manresana de Micobacteriologia, SL
Distal, Subungual Onychomycosis
Study of Different Doses of a Novel Treatment for Onychomycosis
The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.
- Trial name
- NCT00679965
- Testing
- AN2690, 2.5%, AN2690, 5%, AN2690, 7.5%
- Where
- 9 sites in Mexico
- Volunteers
- 159 people
- Sponsor
- Pfizer
Acellular Pertussis, Tetanus
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.
This phase 3b study will compare the immunogenicity and reactogenicity of the dTpa-IPV vaccine to that of a DTPa-IPV vaccine when administered as a booster dose in healthy children 5-6 years of age who have received three primary…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria, Poliomyelitis
- Trial name
- NCT00871000
- Testing
- Boostrix Polio™ 711866, Priorix Tetra TM 208136, Tetravac TM
- Where
- 8 sites in Italy
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Syphilis Infection, Syphilis
Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT
This study is to test the Reveal® TP (Syphilis) antibody POCT (MedMira, Inc., Halifax, Nova Scotia) for its performance in an urban STI clinic in Vancouver, British Columbia and compare its performance in parallel with the usual…
- Conditions
- Syphilis Infection, Syphilis, Early Syphilis, Symptomatic
- Trial name
- NCT05831098
- Testing
- Reveal TP (Syphilis) Antibody Test
- Where
- Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- MedMira Laboratories Inc.
Poliomyelitis
Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia
The purpose of this study is to assess reactogenicity and safety of simultaneous administration of GSK Biologicals' inactivated poliomyelitis vaccine Poliorix and GSK Biologicals' DTPa-vaccine Infanrix vaccines in healthy…
- Trial name
- NCT01094171
- Testing
- Poliorix TM, Infanrix TM
- Where
- 2 sites in Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Group A Streptococcal Infection
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.
- Trial name
- NCT07616934
- Testing
- VAX-A1 Low, VAX-A1 Mid, VAX-A1 High
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
MENINGOCOCCAL INFECTION
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children.
- Trial name
- NCT02531698
- Testing
- Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline
- Where
- 15 sites in Finland, Poland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Disease
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
This is extension of the V102_16 study (NCT02140762). V102_16E1 is designed to assess the effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6 month schedule, against the same panel of…
- Trial name
- NCT02285777
- Testing
- Meningococcal ABCWY
- Where
- 8 sites in United States
- Volunteers
- 189 people
- Sponsor
- GlaxoSmithKline
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on…
- Trial name
- ANIMA - Italy (NCT07543419)
- Where
- 16 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Mycobacterium Infections, Nontuberculous
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung disease.
- Trial name
- NCT01315236
- Testing
- Liposomal amikacin for inhalation (LAI)
- Where
- 19 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Insmed Incorporated
Candidiasis
A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
This is a study to investigate the safety and efficacy of voriconazole for the treatment of candidemia in critically ill non-neutropenic patients
- Trial name
- NCT00163111
- Testing
- VFEND® I.V., Oral, Conventional amphotericin B, Diflucan IV, oral
- Volunteers
- 412 people
- Sponsor
- Pfizer
Tinea Pedis
A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)
In this phase Ib, multi-centre, randomized, double-blind, placebo-controlled parallel group study, 120 subjects with moccasin type tinea pedis (MTTP) will be enrolled at approximately 11 centres in the USA, Canada and Australia.
- Trial name
- NCT00509275
- Testing
- W0027
- Where
- 9 sites in United States, Australia
- Volunteers
- 120 people
- Sponsor
- Stiefel, a GSK Company
Shigellosis, Bacillary Dysentery
SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers
This is a first-in-human, single-center, single-blinded, observer-masked randomized, dose escalation (two doses), placebo-controlled study in healthy volunteers.
- Trial name
- NCT02797236
- Testing
- SF2a-TT15 vaccine, SF2a-TT15 vaccine + adjuvant
- Where
- Israel
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Tuberculosis
A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)
The safety, tolerability and immunogenicity of lyophilized recombinant tuberculosis vaccine (AEC/BC02) were studied in a randomized, blind, controlled phase ⅱ A clinical study in patients 18 years and older with latent infection…
- Trial name
- NCT05284812
- Testing
- Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Bacterial Vaginosis
Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis
This is a phase IIa clinical trial in women with bacterial vaginosis. This study will determine whether treatment with vaginal lactobacillus in combination with antibiotic therapy (metronidazole) is effective in colonizing the…
- Trial name
- NCT00635622
- Testing
- LACTIN-V
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Osel, Inc.
Typhoid
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility.
- Trial name
- NCT00679172
- Testing
- Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3)
- Where
- 3 sites in United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.